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Abstract 
Despite significant advances in cancer diagnostics and treatment, ovarian cancers (OC) continue to 
kill more than 150,000 women every year worldwide. Due to the relatively asymptomatic nature 
and the advanced stage of the disease at the time of diagnosis, OC is the most lethal gynecologic 
malignancy. The current treatment for advanced OC relies on the synergistic effect of combining 
surgical cytoreduction and chemotherapy; however, beside the fact that chemotherapy resistance is 
a major challenge in OC management, new imaging strategies are needed to target microscopic 
lesions and improve both cytoreductive surgery and patient outcomes. In this context, 
nanostructured probes are emerging as a new class of medical tool that can simultaneously provide 
imaging contrast, target tumor cells, and carry a wide range of medicines resulting in better diagnosis 
and therapeutic precision. Herein we summarize several exemplary efforts in nanomedicine for 
addressing unmet clinical needs. 
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Introduction 
Ovarian cancer (OC) is the fourth most common 
cause of cancer deaths in women in the developed 
world claiming more than 150,000 lives per year 
worldwide [1]. Due to the relatively asymptomatic 
nature of OC and advanced disease present at the 
time of diagnosis, this is the most lethal of all 
gynecologic malignancies [2]. In particular, the lack of 
adequate screening tests results in 75% of patients 
being diagnosed at late FIGO (The International 
Federation of Gynecologists and Obstetricians) stages 
(III and IV), suggesting that there is a need for 
improving methods for the early and specific 
detection of OC [3,4]. Clinical data have shown that 
the 5-year survival rates for OC dramatically improve 
when the disease is diagnosed at an early stage [5]. 
However, decades of intense efforts toward 
developing potential screening test have failed to 
identify a clinically applicable strategy for early 
diagnosis of OC [6]. 
Current treatment for advanced OC relies on 
various combinations of surgical cytoreduction with 
chemotherapy [7]. Increasing evidence suggests that 
optimal cytoreductive surgery is the most relevant 
prognostic factor, and the probability of achieving a 
cancer-free state is maximized through a combination 
of maximal debulking surgery and intraperitoneal 
(IP) chemotherapy [8]. Performing a maximal 
debulking surgery, however, requires detecting, 
visualizing, and resecting small sub-millimeter 
tumors, which represents a substantial technical 
barrier. Thus, new imaging techniques and contrast 
agents are needed to target microscopic lesions as well 
as improve cytoreductive surgery and patient 
outcomes [9]. In this new paradigm, IP chemotherapy 
and targeted photodynamic therapy could play a role 
[10].  
The main issue for the patients’ outcome is also 









considering that OC is a heterogeneous disease with 
respect to histological subtypes, molecular biology, 
and disease prognosis, a single standard treatment is 
unlikely to benefit all patients [2]. Since chemotherapy 
resistance is a major challenge in the management of 
OC [11], it is of fundamental importance to identify 
biomarkers able to predict patients’ response to 
available therapies and to choose the more effective 
ones in terms of survival rate and cost to healthcare 
systems [12]. 
We believe that the critical aspects related to 
specific detection and targeting of cancer cells could 
be improved by using nanostructured probes. 
Specifically, nanotheranostics, by integrating imaging 
and drug delivery functions into a single NP 
formulation, offers a promising strategy to monitor 
the drug biodistribution and the pathological process 
longitudinally, yielding vital insights into tumor 
identification and predicting efficacy of therapeutic 
nanomedicines [13]. 
Many preclinical studies have reported the use 
of nanoparticles for imaging and treating OC. Some of 
these nanoplatforms have already been translated into 
clinical practice. In the present review, a general 
overview will be provided concerning the role that 
nanomedicine can play in the clinical management of 
OC. 
Imaging ovarian cancer 
Clinical features of imaging techniques are 
described in Table 1. 
Ultrasound imaging  
Pelvic transvaginal sonography (TVS) together 
with abdominal and pelvic transabdominal 
sonography is the most important procedure for the 
morphological evaluation of OC with the use of the 
Doppler and color Doppler to study mass 
vascularization. Ovarian sonography can be an 
effective strategy to detect the changes regarding the 
size and adnexal architecture preceding both the 
development of symptoms and alterations detectable 
by pelvic examination [14]. Initial studies took into 
account the ovarian volume, which should be less 
than 20 cm3 at fertile age and less than 10 cm3 in 
post-menopausal women [15]. Other studies 
highlighted the importance of integrating the ovarian 
volume with morphological characteristics for 
diagnostic purposes. Studying the presence of septa 
and their thickness, the characteristics of the cystic 
wall, and the presence of papillations, DePriest and 
Sassone found that the sensitivity and the specificity 
in differentiating benign from malign cists were 
between 89% and 100% and between 70% and 83%, 
respectively [16,17]. However, there is significant 
interobserver variability in the interpretation and 
assessment of sonographic images. Indeed, after 
external validation the sensitivity of several 
ultrasound parameters proved to be significantly 
lower [18]. Therefore, it would be useful to find 
common terminology and set up standard parameters 
for sonography as was proposed by the International 
Ovarian Tumor Analysis (IOTA) group. Founded in 
1999, with the aim of standardizing sonographic 
terminology of pelvic masses and of creating 
diagnostic algorithms to identify malignant 
neoplasms, IOTA created a consensus on the 
standardization of ovarian mass terminology, leading 
to increased sensitivity in the differentiation between 
benign and malignant masses [19]. Despite the 
improvements made by IOTA in this field, a 
substantial number of indecisive exams, especially in 
post-menopausal women, were reported [20,21]. 
Furthermore, a review of sonographic exams 
performed before adnexal removal due to a tumor 
demonstrated the lack of specific sonographic 
characteristics to distinguish various stages, 
particularly borderline tumor (BOT) versus stage I 
tumor as well as stage II-III versus stage IV [22]. 
Despite these limitations, according to latest studies, 
IOTA algorithms can identify a particular mass with 
90% sensitivity and 93% specificity [23]. 
Improvement of techniques and execution of 
ultrasound exams were recommended in the 
guidelines provided by the Society of Radiologists in 
Ultrasound [24]. Also, it was pointed out by the UK 
Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) that the development and 
implementation of ultrasound procedures can lead to 
an increase in the identification of ovarian tumors 
[25]. The use of Doppler during ultrasound 
examinations helps in the identification of a mass with 
malignant characteristics. This was demonstrated by 
retrospective reviews of ultrasound examinations 
revealing peculiar Doppler features in malignant 
tumors, including central vascularization and 
different flow characteristics from ilari and peripheral 
vessels [26]. Furthermore, other studies identified 
specific characteristics in the blood flow of ovarian 
tumors such as low resistance, low pulsatility index, 
and central vascularization [27-29]. The use of 
ultrasound contrast agents (the most efficient agents 
include highly compressible gas-filled microbubbles) 
can help to better identify and study blood flow, 
especially in post-menopausal women, to better 
recognize the differences between benign and 
malignant adnexal masses [30,31]. The contrast agents 
for ultrasound molecular imaging (USMI), with 
specific affinity towards vascular biomarkers, are 
currently at an advanced stage of development and 





expected to be in clinical trials including OC. 
Remarkably, Willmann et al. performed a 
first-in-human clinical trial of USMI in patients with 
breast and ovarian lesions using a clinical-grade 
contrast agent (kinase insert domain receptor 
[KDR]-targeted contrast microbubble [MBKDR]) that is 
targeted to KDR, one of the key regulators of 
neoangiogenesis in cancer. This study showed that 
targeted USMI allowed noninvasive detection of KDR 
expression in patients with OC and may be useful in 
malignant/benign lesions differentiation [32]. 
Photoacoustic imaging of ovarian cancer 
Photoacoustic imaging (PAI), a relatively new 
imaging method based on the detection of 
light-excited ultrasound waves, may complement 
existing US screening techniques for improving the 
detection and characterization of OC. In particular, 
PAI might permit early detection of angiogenesis at 
an initial stage by allowing identification of the 
neovascularization [33,34]. Despite a limited tissue 
penetration depth of approximately 5 cm and a 
decline in spatial resolution with increasing depth, the 
integration of PAI with transvaginal ultrasound 
(TVU) may help in reducing these limitations [35,36]. 
In this context, the development of a coregistered 
photoacoustic and US imaging system suitable for ex 
vivo imaging of ovaries has been reported [37]. 
Currently, there is a significant effort to expand 
photoacoustic imaging to clinical applications for 
cancer imaging, including OC. New transvaginal 
imaging devices optimized for OC detection are in 
clinical trials (NCT02110277, NCT02530606). These 
trials are aimed at developing a method for analyzing 
PAI ovarian tissue images by measuring oxy and 
deoxy hemoglobin (Hb) and their ratio to identify the 
presence of ovarian abnormalities and compare US 
and PAI changes. While encouraging data have been 
published by ex vivo studies [37], in vivo human data 
are still scarce [38-40]. In this context, clinically 
translatable contrast agents will need to be developed 
and appropriate biomarkers identified to aid in PAI 
beyond endogenous optical contrast. 
 
 
Table 1. Features of common imaging exams with advantages and disadvantages in clinical practice. 
Type Characteristic Advantages Disadvantages 
Ultrasound Morphologic exam Not expensive 
Safe, no radiation, repeatable 
Real-time (live) exam, not static images 
Very fast 
Small device, doesn’t need a big room 
Useful in emergency 
Small field of insonation 
Operator and device dependent 
Small field 3D 
Not useful in obese patients 
Only soft and cystic tissues 









Uses X-rays for imaging 
Excellent for bones, good for soft and vascular tissues, 
especially with contrast dye 
Large field 
Usually less expensive and quicker than MRI 
The machine is very open, also for obese patients (up to 
200 kg) 
Useful in emergency 
With Multiple Detector Computed Tomography, 
isotropic imaging is possible. Helical scan and 
Multiplanar Reformation reconstruct any plane  
More expensive and slower than ultrasound 
Worse resolution in soft tissue compared to MRI 
Exposure to radiation 
Static images 
Iodized dye with high risk of allergy 












Uses large magnetic external 
fields 
Best resolution, especially in soft tissues vs. CT scan  
Safe, no radiation, repeatable 
Large field 
MRI machines can produce images in any plane. 3D 
isotropic imaging with Multiplanar Reformation 
Expensive exam 
Not useful on bone with respect to CT scan 
Limited accessibility to exam compared to needs 
Contraindicated if metallic objects are present in the 
patient (pacemaker, prosthesis, IUD, etc.) due to 
magnetic field and possible dislocation and damage 
Static images 
Slow exam, depending on size of studied areas (until 2 h) 
Requires patients to lie still for extended periods of time 
Narrow space in the machine, not useful for obese 
patients (up to 150 kg); pay attention to claustrophobic 
and anxious patients 
gadolinium contrast has severe side effects in patients 
with impaired kidney function 
PET/CT Functional exam 
 
Radioactive tracers that emit 
positrons are used. The 
positrons are tracked by the 
system to generate a 3D 
image over time 
PET scans have an advantage over regular CT scans in 
determining the functioning of biological processes 
In a PET scan the imaging technique gets down to the 
cellular level of the body, hence it can detect the early 
onset of disease like cancer, before they start showing 
up in CT scan 
Large field 
Expensive exam 
Slow exam (up to 4 h) 
From moderate to high exposure to radiation 
Photoacoustic Functional exam 
Detection of light-excited 
ultrasound waves  
Early detection of angiogenesis  Limited tissue penetration  
Small field 
Limited to research 
 
 





MRI, PET, and CT imaging of ovarian cancer 
Besides ultrasound, anatomic imaging with 
computed tomography (CT) and magnetic resonance 
(MR) imaging has long been used in clinical practice 
to ascertain disease extent and to detect peritoneal 
disease spread in patients with OC. More recently, the 
combination of anatomic imaging with positron 
emission tomography–computed tomography 
(PET/CT), a functional imaging method, has been 
shown to provide insight into both the molecular 
pathobiology and the disease extent to guide the 
choice of therapy [41]. PET proved to be helpful in 
accurately staging patients, evaluating the 
effectiveness of treatment, and detecting the 
recurrence of cancer. In particular, volumetric 
parameters of PET, using 18F-fludeoxyglucose 
(18F-FDG PET/CT) that comprehensively reflect both 
metabolic activity and tumor burden, could identify 
patients at high risk of recurrence who need more 
aggressive treatment [42]. Moreover, it has been 
shown that PET/CT can improve pre-treatment 
staging accuracy [43]. Thus, the combination of PET 
with anatomic images results in a 
functional/metabolic image providing accurate 
anatomical information.  
Despite the intensive efforts to improve 
diagnostic tools, the goal of effective screening and 
early detection for OC remains elusive. There is a 
critical need to develop better imaging modalities and 
to have a better understanding of disease biomarkers. 
The progressive breakthroughs in medical imaging 
have supported the development of multimodal and 
molecular imaging approaches. Besides developing 
hybrid imaging systems, conjugation of targeting 
moieties with contrast agents can confer specific 
targeting ability to the imaging procedure, with the 
possibility of enabling early detection and diagnosis 
of OC.  
Therapy of ovarian cancer 
Surgery  
Surgical management of OC remains the 
cornerstone treatment of the disease (Figure 1). An 
adequate full surgical staging in women with early 
stage disease has been demonstrated to improve 
outcome. In fact, complete surgical cytoreduction is 
considered to be the only modifiable prognostic factor 
for patients with advanced disease [44]. OC surgery is 
essentially a laparotomic surgery; the laparoscopic 
technique can be used in the early stages, in restaging 
surgery, and in advanced stages for the assessment of 
disease to evaluate the possibility of optimal primary 
cytoreduction [45,46] (Figure 2). 
 
Figure 1. Ovarian cancer surgery overview. Goals of primary surgery for 
ovarian cancer are proper staging (in early disease) and optimal 
cytoreduction/debulking (in advanced disease). Optimal debulking surgery is defined 
as surgery that results in no macroscopic residual disease. Primary debulking surgery 
(PDS) followed by platinum-based chemotherapy is the standard treatment for 
patients with advanced disease. Neoadjuvant chemotherapy (NACT) followed by 
interval debulking surgery (IDS) is an alternative treatment option for patients who 
are unlikely to undergo PDS. Fluorescence image-guided surgery represents a 
promising intraoperative guidance technique to improve debulking completeness. 
 
Figure 2. Surgical treatment of ovarian cancer according to FIGO stages 
and the role of minimally invasive surgery in ovarian cancer (OC). 
According to FIGO stages, in early-stage OC a minimally invasive surgical evaluation 
allows staging of patients and identification of low-risk patients who are candidates for 
fertility-sparing surgery. In advanced-stage OC, a minimally invasive surgical 
evaluation can provide valuable predictive information, delineating patients with 
disease that is amenable to optimal surgical cytoreduction. 






Initial clinical stage (I or II) is observed only in 
one-quarter of patients diagnosed with OC. Prognosis 
is good with 5-year survival rates ranging from 80% to 
95% when recommended treatment is followed. A 
rational surgical scheme with various options is 
presented in Figure 1. According to a Cochrane 
review (The Cochrane Library is a collection of 
high-quality, independent evidence to inform 
healthcare decision-making) [47] and the most recent 
FIGO recommendations [48] in these stages the 
surgical therapy considers the removal of the mass 
and surgical staging, i.e., contralateral annessiectomy, 
hysterectomy, multiple peritoneal biopsies, omentec-
tomy, appendectomy (for mucinous histotype) and 
pelvic and paraaortic lymphadenectomy for 
microscopic disease. These procedures find 
microscopic disease in nearly 18% of women and have 
implications for the prognosis and subsequent patient 
treatment [49]. Moreover, as has been demonstrated, 
inadequate initial surgical staging leads to a higher 
risk of developing recurrent disease despite receiving 
adjuvant chemotherapy [50]. Lymphadenectomy is 
currently recommended at the initial stages and in 
conservative treatments. Appropriate diagnosis and 
staging are even more critical in young and childless 
patients, where a conservative treatment is possible 
with the preservation of both the uterus and the 
contralateral ovary at the initial stages (IA G1-G2, 
with favorable histotype), associated with an 
intensive peritoneal and retro peritoneal staging [51]. 
A review of literature highlighted by a recent 
Cochrane publication [52] showed insufficient data to 
suggest laparoscopic rather than the laparotomic 
approach in early stage surgery, which requires 
further confirmations and longer follow-ups to verify 
its prognostic value and to validate its routine use in 
clinical practice [52,53]. 
Advanced stages 
The most common intervention in late-stage 
disease is the cytoreductive surgery (see Figure 1) 
consisting of total extrafascial hysterectomy with 
bilateral adnexectomy, total omentectomy, 
appendectomy, resection of bulky pelvic and aortic 
lymph nodes, and the removal of all macroscopically 
visible disease including gastrointestinal tract and 
spleen that are often involved. Overall and 
disease-free survivals are inversely proportional to 
the amount of residual disease, showing that the 
post-surgical residual tumor is an independent 
prognostic factor. Therefore, the current definition of 
optimal debulking is no macroscopic disease [55]. 
Systematic pelvic and paraaortic lymphadenectomy, 
compared to a resection of bulky lymph nodes, 
appears to extend the progression-free survival (PFS) 
period without increasing the overall survival (OS); 
however, the complications related to lymphadenec-
tomy are increased [56]. Several studies have 
suggested a favorable role of neoadjuvant 
chemotherapy (NACT) over primary surgery in OC 
[45,57,58]. 
Interval debulking surgery and neoadjuvant 
chemotherapy  
When an optimal cytoreduction is not possible at 
the first operation, the surgical therapy can be 
repeated following chemotherapeutic treatment for 
reducing the neoplastic mass in advanced tumors (see 
Figure 1). There are studies with conflicting results 
[59,60] and, therefore, the usefulness of this technique 
is still controversial. Findings from observational 
studies indicate that patients with no residual disease 
after primary debulking surgery (PDS) might have 
better survival than those who require an interval 
debulking surgery (IDS). Furthermore, it is argued 
that the choice of treatment (PDS versus NACT-IDS) 
and the amount of residual disease after debulking 
surgery is strongly related to the expertise of the 
surgical team [7,61,62]. 
The role of chemotherapy at advanced stages is 
being reviewed to better understand its optimal 
timing. Two published randomized phase III studies 
did not show substantial advantages in terms of OS 
and PFS between PDS and IDS with post-surgical 
tumor residues. There were numerous confounding 
factors between these studies necessitating further 
studies to clarify the effectiveness of this therapy 
[57,58]. For example, the randomized prospective 
SCORPION study compared the role of PDS vs. 
NACT followed by IDS in patients with advanced 
ovarian carcinoma of high intra-abdominal 
disseminated disease with a laparoscopic score. 
Preliminary data, in terms of perioperative 
complications and quality of life were in favor of 
interval surgery [45]. Therefore, if survival data did 
not show a statistically significant advantage for PDS, 
NACT could become the primary approach in this 
subset of patients. For now, the primary surgical 
approach should be taken into consideration at 
advanced stages with the exception of patients with i) 
extra-abdominal disease spread, ii) unfavorable 
Performance Score (PS), iii) elevated ASA (American 
Society of Anesthesiologists classification), and iv) 
when the tumor dissemination does not allow an 
optimal tumor resection. Reduction in residual tumor 
volume has the advantage of increasing the 
penetrability of chemotherapy in cells, increasing the 
response to treatment by synchronizing the 
micrometastatic cell division and reducing the 





number of cycles necessary to eradicate the residual 
disease thus preventing the onset of chemoresistance 
[63]. 
Fluorescence image-guided surgery 
Fluorescence image-guided surgery, because of 
its high sensitivity, low cost, portability, and real-time 
capabilities has excellent potential for improved 
intraoperative staging and more radical cytoreductive 
surgery in metastatic OC patients (see Figure 1). 
Recently, four contrast agents have been used in 
clinical trials for intraoperative fluorescence imaging 
of OC: indocyanine green (ICG), folate-FITC [9], EC17 
[64] and OTL38 [65]. Fluorescence imaging using ICG 
based on the enhanced permeability and retention 
(EPR) effect did not appear well suited for a sensitive 
yet specific detection of OC metastases. Indeed, 
despite detecting all malignant lesions, the lack of 
precise targeting properties led to a high false-positive 
rate [66]. Consequently, there is a demand for the 
development of more tumor-selective contrast agents. 
Of interest is the observation that folate receptor α 
(FRα)-specific contrast agents allowed highly specific 
and accurate tumor imaging with real-time 
identification of cancer cells. In particular, in 12 
patients with OC, OTL38 accumulated in folate 
receptor alpha-positive tumor cells, enabling the 
surgeon to resect an additional 29% of malignant 
lesions that were not identified previously using 
inspection and/or palpation [65]. The fluorophore 
optical properties of these specific contrast agents 
could be further improved to reduce tissue 
autofluorescence and increase penetration depth and, 
thus, clinical relevance of fluorescence-guided 
surgery. 
Chemotherapy 
Postoperative chemotherapy is usually needed 
as an adjuvant treatment in early high-risk disease as 
well as in advanced disease. While remaining an 
independent prognostic factor, the role of surgical 
staging is essential for assigning the patient to proper 
medical treatment. The adjuvant therapy of ovarian 
carcinoma depends on the stage, histological grade, 
and histotype of the neoplasm. The essential 
requirements for an optimal adjuvant treatment are 
the effectiveness of micro-metastatic disease control 
and tolerability regarding short- and long-term side 
effects. The standard approach is the combination of a 
platinum compound, such as cisplatin or carboplatin, 
and a taxane, such as paclitaxel or docetaxel [67,68]. 
The treatment of early OC is surgical resection, 
but as a result of the high risk of recurrence (25-30%), 
many patients receive adjuvant chemotherapy as well 
[69]. Currently, the therapeutic management of 
advanced ovarian carcinoma relies on the correct 
integration between surgical oncology and medical 
oncology. Usually, in advanced disease, surgery is not 
curative and post-surgical chemotherapy has become 
the therapeutic standard for the treatment of this 
neoplasm. However, despite initial efficacy, 70-80% of 
patients with advanced malignancies develop disease 
relapse within the first two years and generally need a 
second line of treatment. Therefore, numerous studies 
have been carried out to improve the efficacy of the 
1st line chemotherapy.  
Intraperitoneal chemotherapy 
Intraperitoneal chemotherapy was developed as 
a new strategy to improve the efficacy of the 1st line 
chemotherapy. Ovarian cancer remains largely 
restricted to the abdominal cavity for most of its 
natural history, making it an ideal target for 
loco-regional therapy as peritoneal tumors are 
directly accessible by intraperitoneal (IP) injections. 
The rationale for the use of IP chemotherapy is based 
on the hypothesis that the IP route treats cells in 
suspension or microscopic disease more effectively 
[70]. Moreover, current IP therapies seem to be 
promising for advanced OC characterized by 
metastatic dissemination into the peritoneum [71]. 
Indeed, a recent update of the Gynecologic Oncology 
Group (GOG) study #s 114 and 172, based on 870 
randomized patients, demonstrated that IP therapy 
led to a significant advantage in 10-year overall 
survival (median 61.8 versus 51.4, HR 0.77). This is the 
most significant survival benefit ever reported in OC 
studies [71]. However, side effects related to this 
administration route hinder its widespread clinical 
use [72,73]. In particular, a survey showed that 
despite encouraging data, only 50% of potentially 
eligible patients in the equipped centers were treated 
with IP chemotherapy. However, the same survey 
confirmed that IP chemotherapy, as opposed to 
intravenous (IV) chemotherapy, produced a 
significant 3-year survival benefit (3y OS HR 0.68) 
[74]. Recently, an opposite result was furnished by 
GOG 252 study, which did not demonstrate a survival 
advantage associated with IP cisplatin and IP 
carboplatin over IV paclitaxel and carboplatin with 
median PFS of 24.9 (IV), 27.3 (IP carboplatin), and 26.0 
(IP cisplatin) months. Also, the GOG 252 study 
showed comparable toxicity in the three arms. Unlike 
previous studies, all three arms in GOG 252 were 
integrated with bevacizumab and the dose of cisplatin 
was lower. Moreover, cross-over to the IV only 
therapy occurred in 16% of patients randomized to 
the IP carboplatin arm and in 28% of patients 
randomized to the IP cisplatin arm. These variations 
might have equalized or negated the clinical 





advantage of IP chemotherapy and reduced the 
toxicity [75]. 
Hyperthermic IP chemotherapy (HIPEC) 
consisting of IP infusion of high temperature 
chemotherapy (43 °C) is used in the treatment of 
recurrent or advanced OC after surgical cytoreduction 
with no residual macroscopic disease. It has been 
shown that cisplatin and other chemotherapeutic 
agents penetrate deeper into tumor tissues under 
hyperthermic conditions and that the neoplastic cells 
become more chemosensitive at 40-43 °C due to an 
increase in intracellular drug concentration and to an 
alteration of the DNA repair mechanisms. Although 
the international consensus group suggested 
combined treatment with surgical cytoreduction and 
HIPEC as the treatment that is most likely to improve 
stage III OC survival, it is currently difficult to assess 
its effectiveness in terms of overall survival and 
disease-free survival. For the above-mentioned 
reasons, HIPEC should only be included in clinical 
research and not in routine treatment [76-77]. 
Therapeutics for ovarian cancer 
Despite the advances in our understanding of 
the origin of OC and its pathogenesis, the available 
pharmacological arsenal for treating OC (Figure 3) 
has been mostly stagnant over the last decade with the 
approval of only two new drugs (olaparib and 
bevacizumab), suggesting a need to improve the 
arsenal of therapeutic drugs for OC. In 2014, the 
European Medicines Agency (EMA) recommended 
granting a marketing authorization for the first 
poly(ADP-ribose) polymerase (PARP) inhibitor 
olaparib (Lynparza®) [78], and in 2015 it was 
approved by the US Food and Drug Administration 
(FDA) [79] as monotherapy for the treatment of 
BRCA-mutated (BReast CAncer susceptibility gene) 
advanced OC. Successive studies showed that 
olaparib, in combination with chemotherapy, 
followed by maintenance monotherapy significantly 
improved progression-free survival versus 
chemotherapy alone, with the most significant clinical 
benefit in BRCA-mutated patients [80]. Bevacizumab 
(Avastin®), approved by the FDA in February 2004 for 
use in metastatic colorectal cancer, is the first 
anti-VEGF monoclonal antibody found to be effective 
in OC. In 2017, the FDA accepted a supplemental 
biologics license application for bevacizumab 
(Avastin®) for the first-line treatment of advanced OC. 
The bevacizumab approval was expanded to include 
two indications in OC: in combination with 
chemotherapy for platinum-resistant recurrent 
ovarian cancer, and combined with platinum-based 
chemotherapy for platinum-sensitive recurrent 
ovarian cancer [81]. So far, bevacizumab has been 
demonstrated to provide significant improvements in 
several clinical trials [82,83].  
Advances in new therapeutics for recurrent OC 
treatment include angiogenesis inhibitors, PARP 
inhibitors, and immunotherapy agents [84]. Current 
immunotherapies for OC include monoclonal 
antibodies, immune checkpoint inhibitors, immune 
 
 
Figure 3. Tools in the pharmacologic arsenal for treatment of ovarian cancer. SERM: selective estrogen receptor modulator; LHRH: Luteinizing-hormone-releasing 
hormone; PARP: poly(ADP-ribose) polymerase. 





modulators, therapeutic cancer vaccines, adoptive T 
cell transfer, oncolytic viruses, and adjuvant 
immunotherapies [85]. Most of these therapies have 
been studied and tested for several decades, but they 
are still in early-phase testing (phase I and II) for OC 
[86,87,88]. Also, the effectiveness of endocrine therapy 
(i.e., a combination of drugs to lower estrogen levels 
in the body) in advanced hormone-sensitive epithelial 
OC is under investigation [89]. The single-agent 
activity of 5 checkpoint inhibitors has been studied in 
OC, but only in phase Ib expansion trials or very small 
phase II trials. Specifically, nivolumab (Opdivo), 
pembrolizumab (Keytruda), avelumab (Bavencio), 
durvalumab (Imfinzi), and atezolizumab (Tecentriq) 
have shown activity between 10% to 15%. To enhance 
the activity of these checkpoint inhibitors, different 
combinations are now under evaluation [90].  
OC treatment is translating into a combination of 
therapeutics whose synergy could enhance the effect 
of a single product. As a newly emerging treatment 
line, the development of combinations of biologic 
agents (angiogenesis inhibitors, PARP inhibitors, and 
immunotherapy) represents a promising approach to 
target multiple cancer-related pathways according to 
the OC genomic complexity [91,92,93]. 
Chemoresistance and targeted therapies in 
ovarian cancer 
OC treatment comprises a combination of 
surgery and chemotherapy, but patients typically 
experience disease relapse despite an initial response 
to chemotherapy. Further treatment can prolong 
survival, although relapse eventually occurs and 
cancer becomes more resistant to therapy. A better 
understanding of the mechanisms that underlie this 
drug resistance may allow treatment to be optimized 
and provide additional information on drugs that are 
more likely to be effective [94]. In particular, the 
identification of pharmacogenomic markers to 
identify patients unlikely to respond to taxane and/or 
platinum therapy would assist in the goal of 
individualizing appropriate treatments for OC by 
combining targeted therapies and avoiding 
administration of ineffective drugs associated with 
unnecessary toxicity [95,96]. 
Nanoparticles for ovarian cancer 
therapies and diagnostics 
Nanoparticles for ovarian cancer in the clinic  
Most conventional chemotherapeutic agents 
have narrow therapeutic indices, develop multidrug 
resistance, and present nonspecific biodistribution 
upon intravenous administration, leading to serious 
side effects to healthy tissues, primarily in the bone 
marrow and gastrointestinal tract. These limitations 
frequently result in suboptimal treatment and 
reduced patient compliance to therapy due to 
excessive toxicities. In this context, nanoparticle (NP) 
drug carriers are emerging as an important modality 
for anti-cancer applications. The main purpose of the 
development of nanodrug delivery systems is to 
improve the bioavailability, tissue uptake, and 
pharmacokinetics of currently available 
chemotherapeutic agents. The majority of the 
available nanodrugs used for cancer therapy are 
liposomes and polymer-based NPs, which decrease 
the toxicity and enhance the delivery of 
chemotherapeutics through the enhanced 
permeability and retention (EPR) effect [97]. 
Furthermore, since tumor cells express many 
molecules on their surface that distinguish them from 
normal cells, targeted NPs are emerging as an 
important class of therapeutic for drug delivery. 
Indeed, NPs can be conjugated with specific ligands 
to enable selective targeting guided by specific 
binding to the tumor cells, providing accumulation of 
the drug in cancer cells [98].  
While some nanomedicine-based drug delivery 
systems have already been marketed and others are in 
clinical trials [99], the majority are still in a preclinical 
stage of development. Among the examples of NPs 
carrying chemotherapeutics approved by FDA as a 
treatment for OC are Genexol-PM®, a polymeric 
micellar formulation of paclitaxel [100], and Doxil®, a 
liposomal formulation of doxorubicin [101]. Of 15 
clinical trials listed on ClinicalTrials.gov with 
“nanoparticle AND ovarian cancer” as search terms 
(Table 2), nine utilize NP platforms for delivery of 
paclitaxel, which is a front-line agent for OC 
chemotherapy. Along with platinum agents, 
development of next-generation NP-based paclitaxel 
is being actively explored. Nanotax®, a 
nanoparticulate paclitaxel, was developed to enhance 
the bioavailability of paclitaxel infused directly within 
the peritoneal fluid without the need for toxic solvents 
such as Cremophor EL, which is responsible for 
hypersensitivity reactions experienced during 
paclitaxel infusion. A recent Phase I clinical trial 
demonstrated that IP administration of Nanotax® 
particles results in higher and prolonged peritoneal 
paclitaxel concentration with lower systemic exposure 
and reduced toxicity compared to intravenous 
paclitaxel administration [102]. Abraxane® is a novel 
nanomedicine that encapsulates paclitaxel into an 
albumin NP (nab-paclitaxel) that is soluble in saline 
solution and facilitates the transport of paclitaxel 
across endothelial cells via an albumin 
receptor-mediated pathway. Since nab-paclitaxel 
exhibits linear pharmacokinetics, it can be 





administered at a relatively higher dose than standard 
intravenous paclitaxel, leading to a higher maximum 
tolerated dose without additional toxicity. 
Nab-paclitaxel was approved by the FDA in 2005 for 
the treatment of breast cancer [103] but has also been 
studied in recurrent OC. In particular, as a single 
agent in phase II, 44 patients with recurrent ovarian, 
peritoneal, or fallopian tube cancer were treated with 
260 mg/m2 nab-paclitaxel intravenously over 30 
minutes every 21 days for 6 cycles. The objective 
response rate was 64% with 15 patients achieving 
complete response and 13 having partial response. 
Toxicities were manageable and no hypersensitivity 
reactions were observed [104]. Another phase II study 
by GOG enrolled 51 patients with platinum- and 
taxane-resistant recurrent OC, out of which 47 were 
evaluable. Nab-paclitaxel at a dose of 100 mg/m2 
intravenously administered on days 1, 8, 15 on a 
28-day schedule was associated with significant 
clinical efficacy and a more favorable side-effect 
profile compared to weekly paclitaxel in this setting. 
The objective response rate was 38%, with one patient 
achieving a complete response and 10 patients a 
partial response (23%) and 17 patients (36%) had 
stable disease. These results are impressive 
considering that all patients were characterized as 
platinum- and taxane-resistant according to standard 
GOG criteria with a very poor prognosis [105]. Several 
other trials of nab-paclitaxel are in progress. In a 
multicenter, multinational phase I/II trial (Trial 
NCT03304210), PIPAC in combination with IV 
nab-paclitaxel is being tested to examine the safety 
and efficacy of the procedure. PIPAC is a novel 
technique recently added to the therapeutic arsenal of 
OC, which enables repeated laparoscopy-aided 
aerosol delivery of chemotherapeutics directly into 
the peritoneum. 
 
Table 2. Registered clinical studies using nanoparticles in ovarian cancer. 
Study title ClinicalTrials.gov 
identifier (phase) 
Commentary 
Intraperitoneal Aerosolisation of Albumin-stabilized 
Paclitaxel Nanoparticles for Recurrent GI and Ovarian 
Cancer 
NCT03304210 
(Phase I, II) 
Pressurized intraperitoneal (IP) aerosol therapy (PIPAC) is a new technological solution for 
the administration of IP chemotherapy, which allows repeated laparoscopy aided aerosol 
delivery of anticancer drugs to the peritoneal cavity. 
Nab (nanoparticle albumin-bound) technology is suitable for encapsulation of other drugs 
(rapamycin, docetaxel).  
Paclitaxel Albumin-Stabilized Nanoparticle 
Formulation in Treating Patients With Recurrent or 
Persistent Ovarian Epithelial Cancer, Fallopian Tube 
Cancer, or Primary Peritoneal Cancer 
NCT00499252 
(Phase II) 
Weekly nab-paclitaxel had noteworthy single-agent activity and was tolerable in this cohort 
of platinum- and taxane- resistant ovarian cancer patients. The median PFS was 4.5 months 
and OS was 17.4 months. The investigators concluded that these parameters are quite notable 
since 70% of the study population had recurred within 3 months of primary treatment 
completion [105]. 
Study of Paclitaxel in Patients With Ovarian Cancer NCT00989131 
(Phase III) 
 
The purpose was to compare the efficacy and safety of paclitaxel micellar nanoparticle 
formulation (Paclical®) and paclitaxel with Cremophor EL used as the solubilizer (Taxol®). 
In results Paclical® showed a positive risk/benefit profile compared to treatment with 
Taxol®; i.e. no need for pre-medication, the infusion time is one hour and possibly a reduced 
risk of experiencing neuropathy. 
Intraperitoneal Paclitaxel Albumin-Stabilized 
Nanoparticle Formulation in Treating Patients With 





Sargramostim and Paclitaxel Albumin-Stabilized 
Nanoparticle Formulation in Treating Patients With 
Advanced Ovarian Cancer, Fallopian Tube Cancer, or 





Patients received Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) 
subcutaneously in combination with nab-paclitaxel. This combination demonstrated 
biochemical responses in a majority of patients, although did not demonstrate an advantage 
in OS over prior studies of nab-paclitaxel monotherapy [128]. 
Paclitaxel Albumin-Stabilized Nanoparticle 
Formulation and Bevacizumab in Treating Patients 
With Stage IV Melanoma That Cannot Be Removed by 




The approach of combining targeted antiangiogenic agents with cytotoxic drugs may lead to 
more effective use of antiangiogenic drugs in the clinic. 
Study to Evaluate CORT125134 in Combination With 
Nab-paclitaxel in Patients With Solid Tumors 
 
NCT02762981  
(Pase I, II) 
 
Recent studies showed that glucocorticoid receptor (GR) activation increases resistance to 
chemotherapy in high-grade serous ovarian cancer. The GR-selective nonsteroidal 
antagonist, CORT125134, inhibits the tumor cell survival effect of GR activation and 
improves sensitivity to chemotherapy [129]. 
Pharmacokinetic, Safety and Efficacy Study of 




Compared to IV paclitaxel administration, IP administration of nab-paclitaxel provides 
higher and prolonged peritoneal paclitaxel levels with minimal systemic exposure and 
reduced toxicity [102]. 
Lapatinib and Paclitaxel in Treating Patients With 
Advanced Solid Tumors 
NCT00313599  
(Phase I) 
Brief high doses of lapatinib (tyrosine kinase inhibitor targeting the Human Epidermal 
Growth Factor Receptor (HER) family) given prior to weekly nab-paclitaxel is a feasible and 
tolerable clinical regimen. Lapatinib may be a novel approach to improving 
chemotherapeutic delivery through vascular-priming chemosensitization [130]. 
Nanoparticle Albumin-Bound Rapamycin in Treating 






Rapamycin present immunosuppressant and potential antiangiogenic and antineoplastic 
activities [131]. The binding of water-insoluble rapamycin to nanoparticle albumin permits 
the albumin-mediated endocytosis of rapamycin by tumor cells and endothelial cells. 





This phase I trial evaluates feasibility of administering TKM-080301 via Hepatic Arterial 
Infusion (HAI) and to characterize the pharmacokinetics and pharmacodynamics of 
TKM-080301 administered by HAI. 





CRLX101 in Combination With Bevacizumab for 





Some preclinical studies have shown that combining antiangiogenic therapy with strategies 
that inhibit tumor hypoxia and expression of hypoxia-inducible factors (i.e. CRLX101) can 
lead to improved anticancer efficacy. Therefore, it has been hypothesized that the 
combination of bevacizumab with CRLX101 might have unique clinical activity [132]. 
Preliminary data from clinical studies of CRLX101 in patients with platinum-resistant 
ovarian cancer suggest that this agent can result in net tumor reductions [133].  
IMX-110 in Patients With Advanced Solid Tumors 
 
NCT03382340  
(Phase I, II) 
 
IMX-110 is a multi-compound nanoparticle which co-deliver low-dose doxorubicin with 
anti-resistance agents (Stat3/NF-kB/poly-tyrosine kinase inhibitor), to disrupt key resistance 
pathways [134]. 
A Study of BIND-014 Given to Patients With 
Advanced or Metastatic Cancer 
NCT01300533  
(Phase I) 
BIND-014 was generally well tolerated, with predictable and manageable toxicity and a 
unique pharmacokinetic profile compared with conventional docetaxel [135]. 






CALAA-01 is the first targeted, polymer-based nanoparticle-carrying siRNA that entered 
clinical trials for cancer. Results of this Phase I clinical trial demonstrate that the siRNA 
delivered via the targeted NPs can engage the RNAi machinery in humans and that siRNA 
can be used as a gene-specific therapy [106]. 
 
 
Beside existing traditional chemotherapeutics, 
we are moving into an age of functional DNA 
sequences and small RNA/DNA molecules to 
precisely target different disease states. In this context, 
NP delivery technologies assist in achieving the 
ability to control and manipulate DNA- and 
RNA-based therapy since the nucleases easily 
degrade native oligonucleotides in biological fluids. 
CALAA-01 employs a novel NP delivery system 
containing non-chemically modified siRNA directed 
against the M2 subunit of ribonucleotide reductase 
(RRM2) and a transferrin (Tf) protein-targeting agent. 
CALAA-01 is the first RNA-carrying NP that entered 
clinical trials for cancer. Results from a Phase I clinical 
trial involving the systemic administration of 
CALAA-01 to patients with solid cancers demonstrate 
that the siRNA delivered via the targeted NPs can 
engage the RNAi machinery in humans and that 
siRNA can be used as a gene-specific therapy. 
Furthermore, these results demonstrate the first 
example of dose-dependent accumulation of targeted 
NPs in human tumors [106]. TKM-080301 is a lipid NP 
formulation containing siRNA against the PLK1 
(polo-like kinase-1) gene product that is often 
overexpressed in cancer and whose inhibitory activity 
in proliferating cancer cells rapidly induces mitotic 
cell cycle arrest and apoptosis. A phase II trial is 
currently ongoing in patients with metastatic liver 
disease (OC with hepatic metastases is included) by 
offering hepatic arterial infusion (HAI) with 
TKM-080301 to patients with unresectable and/or 
life-threatening primary liver cancer or liver 
metastases.  
The concept of personalized or precision 
medicine (PM) has been gaining great interest as a 
promising approach to address unmet medical needs. 
PM relies on the tailoring of the treatment based on 
the patients’ genetic and metabolic profile. Among 
clinical trials on PM, an interesting pilot phase II trial 
investigates NP albumin-bound rapamycin as a 
targeted therapy in patients with advanced cancer 
(OC Stage IIIA, B, C and IV). Patients are identified by 
genetic testing to identify those with a mutation in a 
protein called mammalian target of rapamycin 
(mTOR), which is needed for cell growth and 
division. Patients receive NP albumin-bound 
rapamycin intravenously (IV) over 30 minutes on 
days 1 and 8. The treatment is repeated every 21 days 
for 24 weeks in the absence of disease progression or 
unacceptable toxicity (Trial NCT02646319). 
Nanoparticles for ovarian cancer: future 
perspectives 
Intraperitoneal therapy 
There are no drugs specifically designed and 
FDA approved for IP therapy (except for 
catumaxomab used in malignant ascites); therefore, IP 
administration is considered an off-label use of 
intravenous drug formulations. These drugs have 
suboptimal PK/PD properties for IP therapy [107]. In 
particular, because of the rapid clearance of solution 
from the peritoneal cavity, therapeutic drug 
concentration in peritoneal fluid requires frequent 
dosing schedules and large volume infusion, causing 
local toxicity.  
Nanodrugs have recently been tested in clinical 
trials to improve the therapeutic index (the ratio of the 
toxic to the therapeutic dose) of chemotherapeutic 
agents infused directly into the peritoneum and also 
to obtain improved access to poorly vascularized 
peritoneal tumor nodules. So far, a wide range of NPs 
suitable for ovarian cancer IP therapy have been 
designed and tested in preclinical studies, and the 
characteristics of the most relevant types are 
summarized in Figure 4. In particular, NPs for IP 
delivery have been investigated mainly because of i) 
the ability to manipulate their physical, chemical, and 
biological properties to enhance peritoneal drug 
retention, ii) a chemistry suitable for molecular 
targeting modification, and iii) the ingestion by 
tumor-associated phagocytes that can be exploited to 
either kill tumor cells directly or stimulate antitumor 
immune responses [108]. Indeed, the tumor-homing 
properties of macrophages coupled with their 





capacity to phagocytose NPs represents an intriguing 
approach to optimize delivery of therapeutic agents 
toward tumors as well as lymph node metastases. 
Among the examples of positive correlation of NPs 
and macrophages in OC, sterically stabilized 
superparamagnetic iron oxide NPs (s-SPIONs) 
showed an interesting biodistribution profile 
following IP administration in a SKOV-3 murine 
model [109]. Results showed accumulation of 
s-SPIONs and macrophages in the omentum, which is 
the most common metastatic site for OC. Since it has 
been recently shown that both murine and human 
tumor-associated macrophages express high levels of 
programmed cell death protein 1 (PD-1), and that 
PD-1 expression on tumor-associated macrophages 
correlates with decreased phagocytosis [110], 
strategies to target tumor-associated macrophages 
with specific peptides have been reported [111].  
Despite its advantages, the application of NPs 
for IP delivery is currently hampered by their rapid 
clearance from the peritoneal cavity, mainly caused 
by peritoneal lymphatic drainage. To provide an 
improved therapeutic index for NPs, a balance 
between drug release from the formulations and 
clearance from the peritoneal cavity becomes 
essential. In a recent study [112], a novel form of 
bioadhesive NPs loaded with epothilone B (EB) were 
described to interact with peritoneal tissues, 
dramatically extending their retention in peritoneal 
cancer implants after IP administration. The 
bioadhesive property of these drug nanocarriers is 
based on the general interaction between aldehydes 
on NPs and proteins on tissue, enabling the EB 
concentration to be maintained in the effective range 
at the site of action, thus limiting systemic exposure 
and toxicity. In another study, an in situ crosslinkable 
hydrogel depot containing paclitaxel nanocrystals 
outperformed Taxol® in extending the survival of 
tumor-bearing mice, due to the local depot effect 
[113]. Moreover, expansile NPs (eNP) technology, a 
drug-delivery system specifically designed for the 
treatment of IP malignancies, has been recently 
investigated [114]. Of interest, a significant 
improvement in tumoral drug delivery and efficacy 
was observed with paclitaxel-loaded eNPs compared 
to the standard clinical formulation of paclitaxel 
(Taxol®) in a resection-based OC model. The eNPs 
localize to tumor tissue through a pH-responsive 
mechanism that does not rely on the EPR effect or 
active targeting. In particular, pH-responsive eNP 
swelling drives its selective and prolonged 
accumulation at the target tumor site as well as the 
increased tumoral drug delivery.  
A series of recent studies have demonstrated the 
utility of engineering NPs with “tissue-specific 
targeting” molecules on their surface to improve 
tumor targeting/localization in mice [98]. This results 
in greater efficacy, tissue specificity, and reduced side 
effects. As shown in Figure 4, several moieties for 
targeting OC cells have been investigated to date. 
 
 
Figure 4. Characteristics of the most relevant NP types tested for IP treatment of ovarian cancer in preclinical studies. 






NP-based DNA and RNA delivery systems offer 
exciting opportunities for gene therapy of various 
human tumors including OC. A major open question 
dealing with NP-based gene delivery systems, which 
is fundamental for their translation at a clinical level, 
is the transfection efficiency that is required for an 
effective gene therapy. Long et al. showed that the 
encapsulation of low-dosage paclitaxel in DPP 
(N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylamm
oniummethyl sulfate and monomethoxy 
poly(ethylene glycol)-poly(d,l-lactide) NPs improved 
the gene delivery efficiency and increased the 
expression of vesicular stomatitis virus matrix protein 
(VSVMP), thus exerting a synergistic anticancer effect 
in OC treatment [115]. Another study has shown 
successful transfer of a plasmid encoding the lethal 
DT-A under transcriptional control of the p16 
promoter (i.e., a promoter specifically active in OC 
cells) complexed with PLGA/PBAE polymers [116]. 
Also, conjugation of a Claudin-3/-4-binding peptide 
to the surface of the NP increased gene delivery into 
tumor cells. Cocco and colleagues have used this 
method to allow gene delivery to 
chemotherapy-resistant ovarian tumor cells in vivo 
upon intraperitoneal administration of NPs without 
causing any evident signs of toxicity [116].  
Small-interfering RNA (siRNA) delivery to 
tumor cells is an emerging gene-silencing technology 
with potential for clinical application. Polymeric NPs 
containing cisplatin and pooled siRNAs that 
specifically target multidrug-resistant (MDR) genes 
markedly inhibited tumor growth in xenografted 
models of cisplatin-resistant OC after IP injections 
[117]. Additionally, linking an internalizing human 
epidermal growth factor receptor 2 (HER2) antibody 
to a polymeric nanocarrier improved the functional 
cytoplasmic delivery of siRNA in breast and OC cells. 
Of note, mice bearing IP human ovarian tumor 
xenografts demonstrated 70% target gene suppression 
after treatment with HER2 antibody-directed siRNA 
nanocarriers [118]. Matsui and colleagues showed 
efficient in vivo siRNA delivery of pH-sensitive 
cationic liposomal NPs to peritoneal macrophages, 
which is recognized as a promising drug target in OC 
[119]. In summary, NP-based delivery systems have 
already shown a significant promise for targeted gene 
delivery, and indicate great potential for clinical use 
in OC therapy. 
Fluorescence image-guided surgery 
New contrast agents are needed to increase the 
sensitivity and efficiency of existing intraoperative 
imaging techniques and further enhance their clinical 
benefit. As newly emerging contrast agents for 
fluorescence image-guided surgery of OC, a range of 
fluorescent NPs suitable for image-guided surgery 
have been designed and tested in preclinical studies 
(Table 3).  
 
Table 3. Relevant fluorescent nanoparticle-based technologies 
for image-guided surgery. 
Nanoplatform Properties Ref. 
CF800 liposomes  Liposomes co-encapsulating a 
commercially available CT contrast agent 
iohexol and a clinically approved NIR 
optical dye indocyanine green (ICG) at a 
mole ratio of 1000:1 (iohexol to ICG).  
[120] 
HER‐2-targeted magnetic iron 
oxide nanoparticles (IONPs) 
Enabling optical and MR dual imaging: 
HER-2 affibody targeting ligands were 
labeled with a unique near-infrared 
(NIR-830) dye with excitation/emission 
wavelengths of 800/825 nm, while 
magnetic IONPs provide MRI contrast. 
[121] 
Silicon naphthalocyanine 





It was engineered to be non-fluorescent 
initially via dense SiNc packing within the 
nanoparticle's hydrophobic core, with NIR 
fluorescence activation after accumulation 





Integrating multiple functionalities, 
including PET, NIR fluorescence imaging, 






Dendrimeric nanoparticles coated with 
activatable cell-penetrating peptides 
(ACPPs), labeled with Cy5 and gadolinium. 
ACPPs are predominantly sensitive to 
MMP-2 and MMP-9 in vivo. 
[137] 
Fluorescent gold nanoparticles 
AS1411-DA-AuNPs 
CT/fluorescent imaging platform. Gold 
nanoparticles are conjugated with 
commercial iodine-based contrast agent 
(diatrizoic acid, DA) and aptamer with the 
specific targeting function to nucleolin 
(AS1411). 
[138] 
Fluorescent HA-derived NIRF 
NPs 
 
NIRF contrast agents consisting of 
polymeric nanoparticle formulations 
derived from hyaluronic acid (HA), with 
either physically entrapped indocyanine 




Among the examples of the most promising 
nanoplatforms, a dual-modality computed 
tomography and near-infrared fluorescence nano 
liposomal agent (CF800), specifically designed for 
image-guided surgery applications, has been 
described in multiple preclinical animal models of 
cancer [120]. Although additional studies are needed 
to determine the reproducibility, sensitivity, and 
specificity of this liposome agent, non-invasive 
pre-surgery CT-based tumor lesion localization and 
intra-surgery NIR fluorescence-based lesion detection 
were successfully demonstrated, supporting the 
clinical advancement of CF800 for image-guided 
surgery, which has the potential to improve surgical 
planning and intraoperative guidance. It is of note 
that the same liposome platform can also combine 
different physical imaging properties (i.e., CT, MR 
and PET imaging) with the advantage of ameliorating 





the performance of other image-guided cancer 
therapies such as radiotherapy and drug delivery 
[120]. Using a clinically relevant orthotopic human 
ovarian tumor xenograft model, Satpathy et al. 
showed that HER-2-targeting magnetic iron oxide 
NPs (IONPs) labeled with a near-infrared dye enabled 
non-invasive optical and MR imaging of tumor 
lesions as small as 1 mm in the peritoneal cavity [121]. 
Moreover, the properties of an activatable theranostic 
nanoplatform based on silicon naphthalocyanine 
polymeric NPs were investigated in two murine 
tumor models—a subcutaneous and an IP xenograft 
of human OC. The phototherapeutic efficacy of the 
developed nanoplatform combined with the ability to 
provide successful resection of tumors, hold great 
promise for their application in clinical image-guided 
surgery and combined phototherapy [122].  
Ultrasound-responsive nanoparticles  
Ultrasound-responsive NPs are a class of new 
multifunctional carrier systems that combine imaging 
functionalities with therapeutic properties by 
releasing their drug payload locally in the target 
tissue under the action of ultrasound. The ability of 
ultrasound to induce tumor-localized and controlled 
drug release from NPs, by means of thermal and/or 
mechanical effects, has been widely reported in the 
literature [123-125]. With this approach, NPs function 
as ultrasound contrast agents that provide 
image-guided tumor-targeted therapy. Ultrasound 
shows a number of attractive features as a theranostic 
modality because of its non-invasive nature, 
acceptable safety, low cost, and easy handling. 
Focusing sonication in precise energy delivery 
patterns on the tumor areas with millimeter precision 
is feasible and ultrasound-driven processes may be 
performed toward deeply located body sites through 
laparoscopic or percutaneous means. Among the 
examples of ultrasound-responsive NPs applications, 
substantial reduction of the tumor growth rate was 
achieved for drug-sensitive ovarian carcinoma [126]. 
Recently, alginate-shelled nanodroplets were 
developed for co-delivery of doxorubicin and 
curcumin as nanotherapy of multidrug-resistant 
human OC, and their cancer treatment efficacy was 
evaluated combined with ultrasound irradiation both 
in vitro and in vivo [127]. 
Conclusion 
NPs are emerging as a new class of vehicles for 
the delivery of chemotherapeutic agents in OC. They 
enable tumor-selective delivery of chemotherapeutics, 
thus increasing the efficacy of the treatment while 
limiting exposure in healthy tissues. Also, advances in 
NP synthesis have produced nanoscale imaging 
agents for fluorescence image-guided surgery. 
Contrast agents specific to several imaging modalities 
can be incorporated, simultaneously increasing the 
sensitivity and efficiency of existing intraoperative 
imaging techniques and further enhancing their 
clinical benefit. The ability to selectively detect 
residual tumor cells following the primary surgery of 
OC would be fundamental to providing more reliable 
and accurate cytoreduction. The combination of 
surgery and therapy afforded by the NPs would 
result in improved survival, maximizing the 
probability of achieving a cancer-free state. A rapid 
increase in the number of trials exploiting 
nanotechnology-based therapeutics suggests that this 
emerging field is poised to make a remarkable 
contribution to OC management strategies. 
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